

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

IFITM2 RABBIT PAB

货号: S218956

产品全名: IFITM2 兔多抗 基因符号 1-8D; DSPA2c

UNIPROT ID: Q01629 (Gene Accession - BC009696)

背景: IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronavirus (SARS-CoV), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GPI,2-mediated viral entry, SARS-CoV S protein-mediated viral entry and VSV G protein-mediated viral entry. Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner.

抗原: Fusion protein of human IFITM2

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 30-150; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cancer, Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human tonsil tissue using 218956(IFITM2 Antibody) at a dilution of 1/25(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human tonsil tissue is first treated with the fusion protein and then with 218956(Anti-IFITM2 Antibody) at dilution 1/25.



The image on the left is immunohistochemistry of paraffinembedded Human brain tissue using 218956(Anti-IFITM2 Antibody)



In comparision with the IHC on the left, the same paraffin-embedded Human brain tissue is first treated with fusion protein and then with



Product Description

Pioneering GTPase and Oncogene Product Development since 2010